Description
In the European Union, nirsevimab is indicated for the prevention of respiratory syncytial virus RSV lower respiratory tract disease in neonates and infants during their first RSV season. Nirsevimab was approved for medical use in both the European Union and the United Kingdom in November 2022,[5] in Canada in April 2023, and in the United States in July 2023.
Get Access to BEYFORTUS (nirsevimab-alip) In India
Medvitaz Pharma is equipped to facilitate the distribution of BEYFORTUS (nirsevimab-alip) (prescription medications) worldwide and throughout India upon completion of necessary legal procedures, if applicable.
To inquire about the price of either the branded medication BEYFORTUS (nirsevimab-alip) or the generic version “nirsevimab-alip” for personal use under patient-specific treatment in various cities including Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim, and others in India, please fill out the request form. Upon receiving your request and assessing the delivery process, we will provide you with an estimated price for the medication within 24 hours.
For any inquiries or assistance, please reach out to our Patient Support Team. We are available to assist you from Monday to Friday, between 9:00 and 19:00 IST. You can contact us via email at [email protected], toll-free at +91 8750295029, or through WhatsApp at +91-8750295029.